DNA damage checkpoints cause cell cycle arrest, allowing DNA repair before resumption of the cell cycle. These checkpoints can be activated through several signaling pathways. Checkpoint activators include p53, checkpoint kinase 1 (CHK1), checkpoint kinase 2 and/or MAPKAP kinase 2 (MK2). Many cancer cells lack p53 activity and, therefore, depend on alternative checkpoint activators to arrest the cell cycle following DNA damage. Inhibition of these pathways is expected to specifically sensitize these p53-deficient cells to DNA damage caused by chemotherapy. Using isogenic p53-proficient and p53-deficient cancer cell lines, we show that inactivation of CHK1, but not MK2, abrogates cell cycle arrest following chemotherapy, specifically in p53-deficient cells. However, we show that CHK1 is required to maintain genome integrity and cell viability, and that p53-proficient cells are no less sensitive than p53-deficient cells to CHK1 inhibition in the presence of DNA damage. Thus, combining CHK1 inhibition with DNA damage does not lead to preferential killing of p53-deficient over p53-proficient cells, and inhibiting CHK1 does not appear to be a promising approach for potentiation of cancer chemotherapy.
Introduction
DNA damaging agents have been in use for cancer therapy for decades. It has been suggested that these agents could be potentiated by inhibition of the DNA damage checkpoints (Zhou et al., 2003; Kawabe, 2004; Zhou and Bartek, 2004; Stark and Taylor, 2006; O'Connor et al., 2007; Ashwell et al., 2008; Bucher and Britten, 2008; Lieberman, 2008) . In response to DNA damage, the cell cycle is arrested at specific checkpoints, allowing DNA repair or, if the damage cannot be repaired, activation of programmed cell death (Zhou and Elledge, 2000; Karlsson-Rosenthal and Millar, 2006 ). An important regulator of this response is the tumor suppressor p53. In response to DNA damage, p53 is activated and stabilized by the Ser/Thr kinases Ataxia-Telangiectasia mutated and AtaxiaTelangiectasia-and RAD3-related (Oren, 2003; Meek, 2004; Harris and Levine, 2005) . The activated p53 protein stimulates the expression of p21, which inhibits the cyclin-dependent kinases, resulting in cell cycle arrest at both the G 1 -to-S (G1/S) and the G 2 -to-M (G2/M) transitions (Vogelstein et al., 2000) . In the absence of p53, the G 1 /S checkpoint cannot be properly activated. Intra-S and G2/M checkpoints can be activated through the Ser/Thr kinases checkpoint kinase 1 (CHK1), checkpoint kinase 2 (CHK2) and MAPKAP kinase 2 (MK2). CHK1 is activated by Ataxia-Telangiectasiaand RAD3-related following genotoxic stress, CHK2 is activated by Ataxia-Telangiectasia mutated following double strand DNA breakage such as that caused by ionizing radiation and MK2 is activated by the p38 MAP kinase following ultra-violet radiation or chemotherapy (Abraham, 2001; Bartek and Lukas, 2003; Shiloh, 2003; Manke et al., 2005; Karlsson-Rosenthal and Millar, 2006; Reinhardt et al., 2007) . CHK1, CHK2 and MK2 phosphorylate and thereby inactivate the Cdc25 phosphatases, resulting in inactivation of cyclindependent kinases and cell cycle arrest (Donzelli and Draetta, 2003; Karlsson-Rosenthal and Millar, 2006) .
In about half of human cancers, the activity of p53 is compromised and the G1/S checkpoint fails (Vogelstein et al., 2000; Reinhardt et al., 2007) . It has been suggested that CHK1 or MK2 inhibitors would abrogate the remaining checkpoints in cancer cells lacking functional p53 and this would lead to preferential sensitization of these cancer cells to chemotherapy over normal p53-proficient cells (Zhou et al., 2003; Kawabe, 2004; Zhou and Bartek, 2004; Stark and Taylor, 2006; O'Connor et al., 2007; Ashwell et al., 2008; Bucher and Britten, 2008; Lieberman, 2008) . A recent publication advocated the utilization of MK2 inhibitors, and reported that the G2/M checkpoint in p53À/À ras transformed cells required MK2 (Reinhardt et al., 2007) . In view of these reports concerning the utility of CHK1 and/or MK2 inhibitors as sensitizers of p53À/À cells to chemotherapy, we examined the sensitivity of two isogenic pairs of p53-proficient and p53-deficient cancer cell lines to DNA damaging agents, when CHK1 or MK2 expression was knocked down by small interference RNA (siRNA) or when their catalytic activity was inhibited.
We discuss our results in view of the published literature and question whether there is wide utility for CHK1 or MK2 inhibitors as anti-cancer agents.
Results
CHK1 but not MK2 is responsible for cell cycle arrest of p53 deficient cells in response to chemotherapy We first examined which checkpoint kinase should be inhibited in order to specifically abrogate checkpoints in p53-deficient cancer cells undergoing chemotherapy. We used siRNA to inhibit the expression of CHK1, MK2 or both. To verify the role of p53 in the maintenance of the checkpoint, we used a pair of isogenic cell lines derived from U2OS: U2OS-LacZ À , a p53-proficient cell line stably expressing siRNA against LacZ, and U2OS-p53 À , which stably expresses siRNA against p53 (RaverShapira et al., 2007) . To confirm that U2OS-p53
À have abrogated activity of p53, we measured the effect of Nutlin (Mdm2 inhibitor) on induction of p53-regulated genes. As shown in Figure 1a , Nutlin induced the expression of p21 under basal conditions as well as under cisplatin (CDDP) treatment in U2OS-LacZ À cells, whereas no induction occurred in U2OS-p53 À cells. Moreover, under CDDP treatment, U2OS-LacZ À cells underwent caspase-3 dependent apoptotic cell death, known to be p53 mediated (Figure 1b) , whereas U2OS-p53 -cells did not activate caspase-3, as expected from cells lacking p53.
Western blot analysis confirmed that efficient and specific knockdown of CHK1 or MK2 was achieved within 48 h of transfection and lasted for at least 3 days ( Figure 2a and data not shown). One day post siRNA transfection, cells were exposed to the DNA cross-linker agent CDDP, or the topoisimerase I inhibitor irinotecan, both at concentrations of 10 mM.
To detect checkpoint activation and cell cycle arrest, we used immuno-fluorescence staining for cyclin B1 and 4 0 ,6-diamidino-2-phenylindole staining for heterochromatin, 24 h after application of the chemotherapeutic drugs. Cells that had entered mitosis were identified by the nuclear staining of cyclin B1 and by chromosome condensation (Figure 2bII ). Cells at later stages of mitosis were identified by the morphology of the dividing chromatin (Figure 2bIII ). Cells with micronucleation were also detected ( Figure 2bV ). When no chemotherapeutic drug was administered, 5-8% of the cells that were transfected with non-targeting siRNA were in mitosis in both the cell lines (Figure 2c ). Knocking down CHK1 in p53-proficient U2OS cells resulted in a decrease in mitosis, but not in p53-deficient cells. Knockdown of MK2 had no effect in either cell line. When CHK1 and MK2 were knocked down together, knockdown of MK2 antagonized the effect of CHK1 knockdown in the p53-proficient cells (Figure 2c ).
DNA damage is expected to activate checkpoints, resulting in cell cycle arrest. As expected, exposure of cells that were transfected with non-targeting siRNA to chemotherapeutic drugs dramatically reduced the number of mitotic cells in both the p53-proficient and p53-deficient U2OS cell lines, indicating the onset of cell cycle arrest. In most of these arrested cells, cyclin B1 accumulated in the cytoplasm, indicating that they were arrested at G2 or S phase (Figure 2bIV ). Inhibition of the kinases that are responsible for the onset of the checkpoints is expected to abrogate the cell cycle arrest induced by DNA damage. We indeed found that knocking down CHK1 restored mitosis in the p53-deficient cells, but not in the p53-proficient cells, following treatment with CDDP or irinotecan (Figure 2c ). Thr3-phosphorylation of histone H3 is a marker of cells entering prophase (Dai et al., 2005) . When cells were knocked down for CHK1 and treated with CDDP, U20S-LacZ -(p53-proficient) cells were arrested before prophase, but U20S-p53 À (p53-deficient) cells had an increase in phosphorylated H3, indicating that they were able to proceed into prophase (Figure 2d ).
These results indicate that CHK1 is responsible for the chemotherapy-induced cell cycle arrest in the absence of p53. In contrast, knocking down MK2 did not affect the number of cells undergoing mitosis in either cell line, independent of the status of p53. These results clearly indicate that CHK1, but not MK2, is required for the activation of the DNA damage checkpoint following chemotherapy in these cells. In addition, the combined knockdown of CHK1 and MK2 had a smaller effect than the knockdown of CHK1 alone (Figure 2c ), suggesting that MK2 knockdown is antagonistic to CHK1 knockdown. 
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Abrogation of DNA damage checkpoints drives cells to undergo mitosis in the presence of damaged or improperly replicated DNA. It is expected to result in mitotic catastrophe and cell death due to disturbed segregation of chromosomes during mitosis (Vakifahmetoglu et al., 2008) . Indeed, in U2OS-p53 À cells knocked down for CHK1 and exposed to chemotherapy, we observed an increased number of cells displaying polynucleation, a characteristic of mitotic catastrophe (Figures 2b V and c) .
Checkpoint abrogation by inactivation of CHK1 does not reduce cell survival We next examined whether abrogation of the S and S/G2 checkpoints by CHK1 knockdown is accompanied by a decline in cell viability following chemotherapy. Using time-lapse imaging, we observed that following the administration of CDDP, U2OS-LacZ À cells underwent cell cycle arrest, indicated by the absence of dividing cells for at least 48 h. This was accompanied by cell death, most of which occurred within 48 h of the administration of the drug (data not shown). We then evaluated the short-term survival of cells by staining with methylene blue, 3 days after the application of chemotherapy, a time that allowed the death of damaged cells. DNA damage checkpoints allow the repair of DNA damage before mitotic entry and thus prevent mitotic catastrophe. Therefore, we expected that knockdown of CHK1, which abrogates the checkpoints in p53-deficient but not in p53-proficient cells, would increase cell death following DNA damage specifically in p53-deficient cells. As shown in Figure 3a , there was no significant difference in the survival of p53-deficient and p53-proficient cells following transfection with nontargeting siRNA as control and treatment with irinotecan. p53-deficient cells were slightly more sensitive than p53-proficient cells to CDDP. Knockdown of MK2 did not differentiate between p53-proficient and p53-deficient cells. Contrary to our expectation, following chemotherapy, the knockdown of CHK1 caused similar reductions in the viability of both cell lines, with no preferential sensitization of the p53-deficient cells. In both p53-proficient and p53-deficient cell lines, knock- (Figure 3b ).
To confirm these findings, we used the non-selective CHK1 inhibitor UCN-01, which had been previously shown to abrogate the S and G2/M checkpoints and induce mitotic catastrophe in p53-deficient cells (Wang et al., 1996; Shao et al., 1997; Hirose et al., 2001; Tse and Schwartz 2004; Chen et al., 2006; Levesque et al., 2008) . Like siRNA-mediated knockdown of CHK1, UCN-01 by itself reduced cell viability even without chemotherapeutics (Figures 4a and b) . Similarly to the siRNA-mediated knockdown of CHK1, we found no difference between the survival of the p53-deficient and p53-proficient cells following combined treatment with UCN-01 and chemotherapeutics. When cells were treated with any one of a variety of chemotherapeutic drugs, application of UCN-01 reduced long-term survival by an extent similar to the reduction observed without chemotherapy. We did not observe the expected significant cooperation between CHK1 inhibition and chemotherapy in the p53-deficient cells. Similar results were obtained using another pair of p53-proficient and p53-deficient isogenic cell lines: Control, stably transfected with an empty vector as control and MCF7-p53 -, which stably expresses siRNA against p53 (Brummelkamp et al., 2002) . In both cell lines, concurrent application of UCN-01 with chemotherapeutics resulted in reduced cell viability compared with cells treated with chemotherapeutic agents alone, with no significant difference between the p53-proficient and the p53-deficient cell lines (Figure 4c ). MCF7-p53 À cells were more sensitive to irinotecan than MCF7-Control, and concurrent treatment with UCN-01 caused a further reduction in cell viability, to similar extents in both cell lines. Tse and Schwartz (2004) reported that application of UCN-01 after the topoisomerase I inhibitor SN38 caused more cell death by mitotic catastrophe in p53-deficient HCT116 cells, than did their concurrent administration (Hirose et al., 2001) . We, therefore, examined whether application of UCN-01 subsequent to chemotherapy might achieve selective sensitization of p53-deficient cells to chemotherapy. The sequential treatment did not enhance the death of either p53-deficient cells or p53-proficient cells (Figure 4c) .
Application of the CHK1 selective inhibitor SB-218078 to U2OS cells corroborated these results. Time-course inhibition of CHK1 decreased the survival of U2OS-LacZ À and U2OS-p53 À cells under CDDP treatment to similar extents as measured by clonogenic assay (Figures 5a and c) . Interestingly, the inhibition was maximal at 8 h, as indicated by accumulation of cdc25a in the cells and reduced after 16 h and 24 h. The reduction of cdc25a might be accounted for activation of overlapping regulatory mechanisms such as CHK2 phosphorylation (Falck et al., 2001) .
We further confirmed our results by using another isogenic pair of p53-proficient (HCT116 p53 þ / þ ) and p53-null (HCT116 p53 À/À ) cell lines (Bunz et al., 1998) . Time-course analysis of CHK1 inhibition with the selective CHK1 inhibitor SB-218078 revealed that wild type HCT116 p53 þ / þ and HCT116 p53 À/À cells survived to similar extents under CDDP treatment as measured by clonogenic assay (Figures 5 b and c) .
Inactivation of CHK1 induces DNA damage
Our results show that inhibition of CHK1 activity results in a decline in mitosis even without chemotherapy in U20S-lacZ -cells, but not in U20S-p53 À cells (Figures 2c and d) . This cell cycle arrest might be because of checkpoint activation by p53, suggesting that inhibition of CHK1 by itself induces DNA damage. We examined this by western blot using an antibody against the phosphorylated form of histone H2A.X, (g-H2A.X), a marker for DNA damage (Rogakou et al., 1998) . siRNA was used to knock down CHK1, CHK2, MK2, or all three together, in both p53-deficient and p53-proficient U2OS cell lines (Figure 6a ). As expected, CDDP or irinotecan induced g-H2A.X accumulation in both cell lines (Figure 6b ). Knockdown of either CHK2 or MK2 had little or no effect on the amount of g-H2A.X. In contrast, knockdown of CHK1 induced considerable accumulation of g-H2A.X, irrespective of whether chemotherapeutics were applied, indicating that CHK1 inhibition causes DNA damage (Figure 6b) . Similar results were obtained using p53-proficient and p53-deficient MCF7-derived cells. These cells were knocked down for CHK1, MK2 or both together, as verified by western blot (Figure 6c and data not shown). As for U20S-derived cells (Figure 2b) , knockdown of CHK1 in the p53-deficient MCF7 cell line abrogated the cell cycle arrest induced by CDDP. This can be seen by the depletion in the inactive, phosphorylated form of Cdc2 ( Figure 6c) ; Dephosphorylation of Cdc2 is required for cell cycle progression. Transfection of non-targeting siRNA slightly elevated the amount of g-H2A.X, indicating that the transfection procedure causes some DNA damage. Knockdown of CHK1, but not of MK2, resulted in a substantial increase in the amount of g-H2A.X (Figure 6c) . Again, knockdown of MK2 antagonized the effects of CHK1 knockdown. These results indicate that ablation of CHK1 leads to DNA damage. This DNA damage might account for the cell death caused by CHK1 inhibition.
Discussion
In this study, we examined whether the inhibition of CHK1 or MK2 or of both can be utilized for the selective sensitization of p53-deficient tumor cells to p53, CHK1 and chemotherapy S Zenvirt et al chemotherapy. Using siRNA mediated gene knockdown in two pairs of isogenic cell lines differing only in the expression of p53, we showed that in the absence of p53, the cells are dependent on CHK1, but not on MK2, for checkpoint activation and cell cycle arrest following administration of CDDP or irinotecan. Moreover, we found that MK2 knockdown reduces the effects of CHK1 knockdown on cell cycle arrest, cell survival and the formation of spontaneous DNA damage. These results confirm data from Xiao et al. (2006) , which showed that knockdown of CHK1 abrogated cell cycle arrest induced by camptothecin or doxorubicin in HeLa and H1299 cell lines, which are p53-deficient, whereas knockdown of MK2 antagonizes this effect . Both our results and those of Xiao et al. differ from those obtained for ras-transformed murine embryonic fibroblasts, in which knockdown of p53 makes these cells dependent on MK2 for activation of the G2 checkpoint (Reinhardt et al., 2007) . These differences might stem from the fact that both our studies and those of Xiao et al. used human cancer cells, whereas Reinhardt et al. (2007) used ras transformed mouse embryonic fibroblasts.
Selective abrogation of the checkpoints in p53-deficient cells, by inhibition of CHK1, was expected to sensitize cells to DNA damage, whereas the unperturbed p53, CHK1 and chemotherapy S Zenvirt et al p53-dependent checkpoint(s) in p53-proficient cells were expected to allow DNA repair and thereby to prevent the sensitization of normal cells to DNA damage (Zhou et al., 2003; Kawabe, 2004; Zhou and Bartek, 2004; Bucher and Britten, 2008; Lieberman, 2008) . As predicted by this model, we observed ( Figure 2c ) that knockdown of CHK1 in p53-depleted cells induced mitotic catastrophe and polynucleation, which results from mitotic entry of cells with damaged DNA (Vakifahmetoglu et al., 2008) . However, unexpectedly, we found that short-term cell survival, as well as the long-term ability to form colonies under CHK1 depletion was similar in the isogenic cell lines regardless of the status of p53 (Figure 3 ). Other studies found, as we did, that the effect of UCN-01 and SB-218078 on cell survival was not dependent on the status of p53 (Hirose et al., 2001; Tse and Schwartz 2004; Levesque et al., 2008) . These studies employed several p53-active and p53-inactive cancer cell lines. To explain these findings, it was suggested that the p53 proficient cell lines that were used had defective p53 signaling, which could not properly activate cell cycle arrest, so that, when CHK1 was inhibited, these cells underwent aberrant mitosis without cytokinesis and died like p53-deficient cells (Levesque et al., 2008; Zhang et al., 2008) . In our study, however, the p53-proficient U2OS cells had intact p53 
U2OS:
Figure 5 The effect of SB-218078 on cell viability: p53-proficient U2OS-LacZ À and p53-deficient U2OS-p53 À cells (a) and HCT116 carcinoma cells carrying wild type p53 (p53 þ / þ ) and p53 null (p53 À/À ) (b) were mock treated (for the 0 h treatment) or supplemented with 5 mM SB-218078. 1 h later CDDP was added at 1.25 and 2.5 mM for 0 h, 4 h, 8 h, 16 h and 24 h. Then the cells were plated in 6 well plates (800 cells per well) for clonogenic assay. 14 days later (for the U2OS cells), or 7 days later (for the HCT116 cells), the cells were assayed for viability with methylene blue. All the colonies were stained regardless of colony size. Viable cells are presented as percent of control, untreated cells. (c) Western blots confirming the CHK1 inhibition. Cdc25a accumulation indicates the inhibition of CHK1. b-catenin is presented as a loading control.
p53, CHK1 and chemotherapy S Zenvirt et al signaling (Figure 1) , were arrested following DNA damage and did not enter mitosis even in the absence of CHK1 (Figures 2c and d) .
Contrary to these results, other groups reported that UCN-01 and other CHK1 inhibitors, when combined with DNA damaging agents, reduced the efficacy of colony formation of p53-inactive cell lines more drastically than that of their isogenic p53-active cell lines (Wang et al., 1996; Shao et al., 1997; Chen et al., 2006) . In these and other studies, UCN-01 and other CHK1 inhibitors, as well as CHK1 knockdown, were reported to potentiate the toxicity of DNA damaging agents (Wang et al., 1996; Shao et al., 1997; Hirose et al., 2001; Tse and Schwartz 2004; Chen et al., 2006; Levesque et al., 2008) . We observed significant toxicity caused by CHK1 inhibition, which appeared to be additive to the toxicity of the chemotherapeutic drugs. CHK1 toxicity may be more pronounced in the cell lines that we used in this study. Our data showed that CHK1 inhibition reduces viability regardless of the status of p53 and does not cooperate with chemotherapeutic drugs to selectively reduce viability of p53 deficient cells. The question remains why checkpoint abrogation by CHK1 inhibition, which is selective for p53-deficient cells, does not reduce their short and long-term survival compared with p53-proficient cells following DNA damage. In both cell lines studied here, knockdown of CHK1 led to a reduction in cell viability. This was accompanied by DNA damage in all cell lines even without chemotherapeutic drugs and by a reduction in the number of mitotic entries in p53-proficient cells, as expected to the event of DNA damage. These findings suggest that in addition to its role in checkpoint activation, CHK1 is involved in maintenance of DNA integrity and is indispensable for cell survival. Supportive of this view, Cho et al. (2005) found that CHK1 is required for the resumption of mitosis after checkpoint activation by hydroxyurea. This requirement for CHK1 to re-enter the cell cycle might reflect its role in the stabilization of stalled replication forks during the S phase arrest. In the absence of CHK1, replication forks collapse and replication cannot be resumed correctly, causing spontaneous DNA damage and cell death (Cho et al., 2005; Petermann and Caldecott, 2006) . Thus, when CHK1 is inhibited and DNA is damaged, p53-proficient cells are not more viable than p53-depleted cells: p53-deficient cells cannot activate checkpoints in the absence of CHK1 and die by mitotic catastrophe. p53-proficient cells can indeed activate DNA-damage checkpoints through the p53 pathway, but cannot re-enter the cell cycle in the absence of CHK1. Therefore, both p53-proficient and p53-deficient cells eventually die. Supportive of this suggestion, it has been reported that when treated with UCN-01, p53-proficient U87MG and HCT116 cells undergo senescence following DNA damage, which indicates their exit from the cell cycle (Hirose et al., 2001; Tse and Schwartz, 2004) . A recent study by Tao et al. (2009) that examined the response of HCT116 colon carcinoma cells to the selective CHK1 inhibitor Chir-124 following ionizing radiation (Tao et al., 2009) confirmed the results of our study. These authors showed that the effect of Chir-124 radiosensitization was similar in p53-deficient and p53-proficient cells and operate through distinct pathways, namely mitotic catastrophe in p53-deficient and another pathway in p53-proficient cells (Tao et al., 2009) , similarly to our observations. In our study, the p53-proficient cells underwent caspase-3-dependent apoptosis, whereas the p53-depleted cells underwent caspase independent cell death ( Figure 1) . These results suggest that the status of p53 might determine the mechanism of cell death and survival, but does not necessarily affect the degree of cell survival under CHK1 inhibition. It has been shown earlier that inhibition of hub proteins may change the mechanism of cell death, but is not necessarily coupled to the extent of cell death, upon application of genotoxic stress (Kravchenko-Balasha et al., 2009 ). In the current study, although CHK1 inhibition selectively abrogates cell cycle arrest following chemotherapy only in p53-deficient cells, the degree of cell death and viability is not affected by p53 status.
In conclusion, CHK1, but not MK2, appears to be the gatekeeper of checkpoint activation in p53-deficient cancer cells. Inactivation of CHK1 abrogates cell cycle arrest following chemotherapy in p53-deficient cells but not in p53-proficient cells and this checkpoint abrogation results in cell death by mitotic catastrophe. However, p53-deficient cells are not more sensitive than p53-proficient cells to the combination of CHK1 inhibition and chemotherapeutic agents. CHK1 is necessary for checkpoint activation and consequent repair in p53-deficient cells, but is also necessary for the recovery of p53-proficient cells following cell cycle arrest. Depletion of p53 changes the mechanism of cell death, but does not cooperate with CHK1 inhibition to increase the degree of cell death.
Most notably, inhibition of CHK1 does not cooperate with DNA damaging agents. Rather, CHK1 is necessary for cell viability and recovery from checkpoint arrest and CHK1 inhibition causes additional DNA damage, which might provide CHK1 inhibitors with nonselective therapeutic activity, like other DNA damaging agents. Indeed, clinical trials have revealed that UCN-01 has some therapeutic effect when not combined with chemotherapy (Senderowicz, 2003) . We conclude that CHK1 inhibitors cannot selectively target cancer cells, based on their deficiency in p53. This conclusion is mirrored by the view of radiation oncologists that the status of p53 does not correlate with the clinical outcome of radiation therapy and chemotherapy (Finkel, 1999) .
Materials and methods

Cell culture and transfections
All cells were maintained at 37 1C in a 5% CO 2 humidified incubator. MCF7 human breast cancer cells, stably transfected with empty pSUPER vector (MCF7-Control) or with short hairpin RNA against p53 (MCF7-p53 À ) (Brummelkamp et al., 2002) , were a gift from R Agami (Amsterdam, The Netherlands). U2OS human osteosarcoma cells stably expressing short hairpin RNA against lacZ (U2OS-LacZ À ) or p53 (U2OS-p53 À ) (RaverShapira et al., 2007) were kindly provided by Professor M Oren (Weizmann Institute, Israel). These cells were grown as monolayers in Dulbecco's modified Eagle's medium (DMEM; Biological Industries, Kibbutz Beit Haemek, Israel) with 10% fetal bovine serum (FBS, Sigma-Aldrich, St Louis, MO, USA) and 1% penicillin-streptomycin (Biological Industries), supplemented with 1 mg/ml puromycin (Sigma-Aldrich) for the MCF7-derived cells, or 2 mg/ml puromycin for the U2OS-derived cells. HCT116-p53 þ / þ and the p53-null derivative HCT116-p53 À/À (Bunz et al., 1998) were kindly provided by Professor B Vogelstein (Johns Hopkins Kimmel Cancer Center, Baltimore). These cells were grown as monolayers in McCoy's medium (Biological Industries) with 10% fetal bovine serum (FBS, Sigma-Aldrich) and 1% penicillin-streptomycin (Biological Industries).
Transfection of siRNA (siGENOME SMARTpool, Dharmacon, Lafayette, CO, USA) was performed with DharmaFECT 1 reagent according to the manufacturer's instructions.
Western blotting and antibodies Cells were washed with phosphate buffered saline (PBS) and harvested by scraping in boiling sample buffer. Total cell extracts (40 mg protein) were resolved on SDS-10% polyacrylamide gel, electroblotted to a nitrocellulose membrane (Watman, Protran, Maidstone, Kent, UK) and reacted with the appropriate antibodies. Bands were visualized by ECL chemiluminescence. The following antibodies were used: Rabbit anti-MK2 (#3042), CHK1 (#2345), P15Y-cdc2 (#9111), GAPDH-14C10 (# 2118) or phospho-Histone H3 (Thr3) (#9714) (Cell Signaling Technology); Mouse anti-cdc25a (#7389) (Santa Cruz Biotechnology, Santa Cruz, CA, USA), Mouse anti-g-histone H2A.X (Upstate Biotechnology, Lake Placid, NY, USA); Rabbit anti-CHK2 (#8108) (Abcam, Cambridge, MA, USA) Rabbit anti-p53-FL393 (#6243) (Santa Cruz Biotechnology); Fluorescein (FITC)-conjugated speciesspecific Donkey anti-Mouse, peroxidase-conjugated AffinPure Donkey anti-Mouse and peroxidase-conjugated AffinPure Goat anti-Rabbit (Jackson ImmunoResearch Laboratories Inc., West Grove, PA, USA).
Immunofluorescence Cells growing on 12 mm coverslips were fixed with ice-cold methanol for 10 min. After rehydration with PBS, cells were permeabilized with 0.5% Triton X-100 in PBS, washed with PBS and then blocked with 5% bovine serum albumin in PBST (PBS þ 0.05% Tween 20). Samples were incubated for 1 h with primary antibody, washed and incubated with secondary antibody, and 4 0 ,6-diamidino-2-phenylindole for 30 min in the dark, then washed and sealed with Fluorescent Mounting Medium (DakoCytomation, Glostrup, Denmark) and visualized with an Olympus IX70 inverted microscope. In each treatment, 80-300 cells from at least two separate fields were examined.
p53 activity assay Cells were plated in 6-well plates at 2800 cells/well. After 1 day, Nutlin and CDDP were applied as indicated for 24 h, and then cell lysate was taken for western blot analysis.
Cell survival assay Cells were plated in 96-well plates at 3000 cells/well. After 1 day, drugs were applied as indicated. After 3 additional days, the methylene blue assay was performed (Dent et al., 1995) . Briefly, cells were fixed with 0.5% glutaraldehyde, stained with 1% methylene blue in 0.01 M borate buffer (pH 8.5), washed and dried and then incubated with 100 ml of 1 N HCl for 1 h at 37 1C. Optical density was measured with an ELISA plate reader at 630 nm.
Clonogenic assay
Cells were transfected as indicated and 48 h later were plated in 6-well plates at 800 cells/well. After 1 day, CDDP was applied as indicated. After 24 h, the medium was replaced by fresh medium and after 10 additional days, the methylene blue assay was performed. All colonies were stained regardless of colony size.
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